Verdict TRUE

TRUE — The FDA approved the first CRISPR-based gene therapy in the United States in December 2023 Is Real

Verified on July 20, 2026

The FDA approved Casgevy on December 8, 2023, marking the first U.S.

Confidence82%

How strongly independent, cited sources support this verdict.

Claim reviewed

The FDA approved the first CRISPR-based gene therapy in the United States in December 2023.

Analysis summary

The FDA approved Casgevy on December 8, 2023, marking the first U.S. authorization of a CRISPR-based gene therapy.

Evidence profile

78 / 100 weighted evidence score H:2 / M:0 / L:0

Key findings

  • The FDA approved Casgevy on December 8, 2023, marking the first U.S.

Sources

Analyzed across 2 independent publishers

FDA Approves First Gene Therapies to Treat Patients with ... Fda
High credibility 78/100
government_primaryInstitutional domain
FDA approves CASGEVY, the first CRISPR/Cas9 gene ... - PMC Nih
High credibility 78/100
government_primaryInstitutional domain

Citations

Copy formatted citations from the verified sources above.

Need to verify another claim?

Open Claims Radar to analyze headlines, posts, or links with live source checks.

Verify a claim
Explore more trending fact checks
Verified by Claims Radar
Possum Mattern Studios